Literature DB >> 16461764

More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders.

David P Steensma, Animesh Pardanani, William S Stevenson, Rosemary Hoyt, Hiu Kiu, Andrew P Grigg, Jeff Szer, Surender Juneja, Douglas J Hilton, Warren S Alexander, Andrew W Roberts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16461764      PMCID： PMC1895422          DOI： 10.1182/blood-2005-09-3646

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  18 in total

1.  Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

Authors:  Alessandro Maria Vannucchi; Lucia Bianchi; Cristina Cellai; Francesco Paoletti; Rosa Alba Rana; Rodolfo Lorenzini; Giovanni Migliaccio; Anna Rita Migliaccio
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

2.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

3.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Authors:  David P Steensma; Gordon W Dewald; Terra L Lasho; Heather L Powell; Rebecca F McClure; Ross L Levine; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

4.  A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis.

Authors:  Lawryn H Kasper; Fayçal Boussouar; Paul A Ney; Carl W Jackson; Jerold Rehg; Jan M van Deursen; Paul K Brindle
Journal:  Nature       Date:  2002-10-17       Impact factor: 49.962

5.  Studies of the human c-myb gene and its product in human acute leukemias.

Authors:  D J Slamon; T C Boone; D C Murdock; D E Keith; M F Press; R A Larson; L M Souza
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

6.  A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis.

Authors:  M L Mucenski; K McLain; A B Kier; S H Swerdlow; C M Schreiner; T A Miller; D W Pietryga; W J Scott; S S Potter
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

7.  Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling.

Authors:  Marina R Carpinelli; Douglas J Hilton; Donald Metcalf; Jennifer L Antonchuk; Craig D Hyland; Sandra L Mifsud; Ladina Di Rago; Adrienne A Hilton; Tracy A Willson; Andrew W Roberts; Robert G Ramsay; Nicos A Nicola; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

8.  Identification of alternatively spliced transcripts for human c-myb: molecular cloning and sequence analysis of human c-myb exon 9A sequences.

Authors:  P Dasgupta; E P Reddy
Journal:  Oncogene       Date:  1989-12       Impact factor: 9.867

Review 9.  Impaired GATA-1 expression and myelofibrosis in an animal model.

Authors:  Alessandro M Vannucchi; Lucia Bianchi; Francesco Paoletti; Viviana Di Giacomo; Giovanni Migliaccio; Anna Rita Migliaccio
Journal:  Pathol Biol (Paris)       Date:  2004-06

10.  v-Myb DNA binding is required to block thrombocytic differentiation of Myb-Ets-transformed multipotent haematopoietic progenitors.

Authors:  J Frampton; K McNagny; M Sieweke; A Philip; G Smith; T Graf
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598
View more
  7 in total

1.  Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl.

Authors:  Nan Xiao; Suparna Laha; Shankar P Das; Kayla Morlock; Jonathan L Jesneck; Glen D Raffel
Journal:  Blood       Date:  2014-12-02       Impact factor: 22.113

2.  Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.

Authors:  Lan Zhang; Xingnong Ye; Shuna Luo; Xiaofei Xu; Shengjie Wang; Keyi Jin; Yan Zheng; Xiaoqiong Zhu; Dan Chen; Jie Jin; Jian Huang
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-22       Impact factor: 4.553

Review 3.  Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia.

Authors:  Lars U W Müller; David A Williams
Journal:  Mutat Res       Date:  2009-04-02       Impact factor: 2.433

4.  Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.

Authors:  E K Engle; D A C Fisher; C A Miller; M D McLellan; R S Fulton; D M Moore; R K Wilson; T J Ley; S T Oh
Journal:  Leukemia       Date:  2014-09-25       Impact factor: 11.528

5.  MYB deregulation from a EWSR1-MYB fusion at leukemic evolution of a JAK2 (V617F) positive primary myelofibrosis.

Authors:  Tiziana Pierini; Danika Di Giacomo; Valentina Pierini; Paolo Gorello; Gianluca Barba; Anair Graciela Lema Fernandez; Fabrizia Pellanera; Tamara Iannotti; Franca Falzetti; Roberta La Starza; Cristina Mecucci
Journal:  Mol Cytogenet       Date:  2016-09-01       Impact factor: 2.009

6.  Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression.

Authors:  Lawryn H Kasper; Tomofusa Fukuyama; Stephanie Lerach; Yunchao Chang; Wu Xu; Song Wu; Kelli L Boyd; Paul K Brindle
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

7.  Predicting pathogenic genes for primary myelofibrosis based on a system‑network approach.

Authors:  Shu-Cai Xu; Peng Ning
Journal:  Mol Med Rep       Date:  2017-10-20       Impact factor: 2.952
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.